Zinc hyaluronate 0.15% eye drops preservative free
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 10 · 1979–2026
Showing the 50 most relevant studies, sorted by most relevant.
B. Ang, J. Sng, P. Wang, et al.
Scientific Reports, 2017
Hyemin Kim, Hyeonseon Jeong, Seulgi Han, et al.
Biomaterials, 2017
Machava RO, Magunga BT, Ntuli SM, et al.
2026
Diabetic foot ulcers (DFUs) constitute a significant global health burden; however, the influence of environmental heavy metals toxicity on their pathogenesis remains insufficiently investigated, particularly within low- and middle-income countries. This systematic review, conducted in strict accordance with PRISMA 2020 guidelines, assesses the impact of heavy metals exposure on the development, progression, and wound-healing kinetics of DFUs. A comprehensive search across PubMed/MEDLINE, Embase, Scopus, and Web of Science identified 32 eligible original studies. Quality appraisal was performed using the Newcastle-Ottawa Scale and SYRCLE's Risk of Bias tool. Synthesized epidemiological and toxicological data consistently indicate that chronic exposure to non-essential heavy metals, specifically cadmium and lead, significantly augments DFU prevalence and clinical severity, demonstrating a 64% increase in DFU prevalence for each 1 µg/L increase in blood cadmium concentration. Mechanistically, these xenobiotics induce a 'chronic inflammatory lock' characterized by severe oxidative stress, sustained NLRP3 inflammasome activation, and the suppression of protective Metallothionein 2A (MT2A) pathways, thereby impeding microvascular angiogenesis. Conversely, deficiencies in essential trace elements, such as zinc and selenium, actively impair extracellular matrix maintenance. Advanced therapeutic interventions, including metal-ion-releasing hydrogels, cell-free exosome therapies, and systemic EDTA chelation, demonstrate significant potential to counteract heavy-metal-induced cellular suppression and facilitate tissue repair. This review underscores the imperative of integrating environmental toxicant screening and targeted detoxification strategies into standard multidisciplinary diabetic foot management.
Abstract licence: CC BY
Yan Liu, Jia-shun Wu, W. Fei, et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2017
Yan Wen, Xiaocheng Zhang, Mao-Sheng Chen, et al.
Annals of palliative medicine, 2020
Yong-Beom Park, C. Ha, Choong-hee Lee, et al.
Stem Cells Translational Medicine, 2016
Wei-Jiang Yu, Guo-Hua Jiang, Yang Zhang, et al.
Materials science & engineering. C, Materials for biological applications, 2017
Xin-Yu Jia, Si-li Jing, Yang Sun, et al.
BMC Oral Health, 2024
X. Bao, Jie-Wen Tan, Michael Flyzik, et al.
Journal of rehabilitation medicine, 2018
Najiya V. Pallikkara, Shweta Nagesh, Pugalmani Sivashanmugam, et al.
Biomaterial Investigations in Dentistry, 2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.